Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;46(5):100892.
doi: 10.1016/j.currproblcancer.2022.100892. Epub 2022 Aug 11.

Tailoring antiHer2 treatment strategies in breast cancer and beyond

Palma Fedele  1 , Valeria Sanna  2 , Anna Natalizia Santoro  3 , Maria Laura Iaia  3 , Alessandro Fancellu  4
Affiliations
Review

Tailoring antiHer2 treatment strategies in breast cancer and beyond

Palma Fedele et al. Curr Probl Cancer. 2022 Oct.

Abstract

Precision medicine advances are opening new opportunities in the treatment of Her2 driven cancers. Her2 signaling activation was found in around 20% of breast cancers about 3 decades ago and define an aggressive subtype of the disease. Nowadays antiHer2 targeted approach is standard of care in both metastatic and early-stage Her2 -positive breast cancer and has changed the general course of the disease. However, the challenge of personalizing cancer treatments through de-escalation and escalation strategies is still open, especially in the early setting of the disease. New evidences are emerging on the role of Her2 dysregulation in the carcinogenesis of solid tumors other than breast cancer. Recently reported clinical trials of antiHer2 targeted therapies have shown promising results in a variety of tumors, especially gastrointestinal and lung cancers. In this review we report challenges and opportunities of tailored antiHer2 treatments in breast cancers and beyond based on the results of recent clinical trials.

Keywords: AntiHer2 therapy; Breast cancer; Gastrointestinal cancer; Lung cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest related to this study. All authors declare no financial and personal relationship with other people or organizations that could inappropriately influence (bias) their work.